Posted by Michael Wonder on 20 Jun 2024
Aurion Biotech receives breakthrough therapy designation and regenerative medicine advanced therapy designation for its drug candidate AURN001
19 June 2024 - First allogeneic cell therapy to receive both FDA designations for the treatment of corneal oedema secondary to corneal endothelial disease.
Aurion Biotech today announced that the US FDA has granted both breakthrough therapy designation and regenerative medicine advanced therapy designation for AURN001, the Company’s allogeneic cell therapy candidate for the treatment of corneal oedema secondary to corneal endothelial disease.
